

Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines

GUI-QIN LING, DONG-BO CHEN, BAO-QING WANG and LAN-SHENG ZHANG

The Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221006, P.R.China

Received June 13, 2012; Accepted September 6, 2012

DOI: 10.3892/ol.2012.916

Abstract. Previous studies have demonstrated that pluripotency-associated transcription factors, such as Oct3/4, Nanog and Sox2, play a crucial role in the development and malignant progression of various types of tumors. Breast cancer is the most frequent cancer among females, being a heterogeneous disease, with distinct morphologies, metastatic behavior and therapeutic responses. The expression of Oct3/4, Nanog and Sox2 in 3 human breast cancer cell lines, MCF7, T-47D and MDA-MB-231, was determined. The expression of Oct3/4, Nanog and Sox2 mRNA was determined by reverse transcription polymerase chain reaction (RT-PCR) and protein expression was detected by immunocytochemistry. RT-PCR revealed that all three human breast cancer cell lines tested expressed evident Oct3/4, Nanog and Sox-2 mRNA at various levels. Higher levels of Oct3/4 were identified in MCF7 and MDA-MB-231 cells compared with T-47D cells. Higher levels of Nanog were observed in MCF7 and T-47D cells compared with MDA-MB-231 cells and the highest expression of Sox-2 was detected in MCF7 cells. The nuclear localization of Oct3/4, Nanog and Sox-2 was confirmed by immunostaining. Oct3/4, Nanog and Sox2 were expressed in human breast cancer cell lines. Further studies are required to characterize the role of Oct3/4, Nanog and Sox2 in human breast cancer.

Introduction

Breast cancer is the most frequent cancer among females. It is a heterogeneous disease, with distinct morphologies, metastatic behaviour and therapeutic responses. Breast cancer is now the most common cancer in developed and developing countries, with 690,000 new cases estimated in each region. Incidence rates are higher in the developed regions of the world than in the majority of developing regions (1). Despite advances in early detection, approximately 30% of patients with

early-stage breast cancer have recurrent disease. Although the systemic treatment of patients with chemotherapy, hormonal therapy and immunotherapy produces a high response rate initially, progression invariably occurs following a variable time interval (2). It remains the most frequent cause of cancer mortality in females in developing and developed countries. To improve the patient survival rate, elucidation of the underlying molecular mechanisms of the tumorigenesis of breast cancer is required. Previous studies have demonstrated that core transcription factors, such as Oct3/4, Nanog and Sox2, involved in the maintenance of pluripotency and self-renewal in embryonic stem cells (ESCs), have been identified in tumors of various origins (3).

Oct3/4, also known as OCT 3, OCT 4 and POU5F1, is one of the earliest transcription factors expressed in the embryo and is encoded by a homeobox-containing gene named Pou5f1 belonging to the family of Pit Oct Unc (POU) genes and recognized as fundamental in the maintenance of pluripotency and self-renewal in ESCs and in primordial germ cells (4). Nanog is also a homeodomain transcription factor thought to be a key factor in sustaining the pluripotency of ESCs (5). Oct3/4 and Nanog expression have been identified in certain human tumors (6). Studies of Oct3/4 and Nanog have revealed that they are specific markers for seminoma/germinoma and embryonal carcinoma in primary testicular and central nervous system (CNS) tumors (7-10). The importance of Oct3/4 has also been demonstrated in the diagnosis of metastatic seminoma and embryonal carcinoma (11). In addition, the ectopic expression of Oct3/4 and Nanog induced an oncogenic potential in epithelial cells and NIH3T3 cells (12,13). The genetic expression of Oct3/4 and Nanog and the protein expression of Nanog have been identified in breast carcinoma and the MCF7 breast carcinoma cell line (6,14). Sox-2, a member of the SRY-related HMG-box family of transcription factors, regulates ESC pluripotency and is also expressed in many tumors (15-17). Previous studies of Sox-2 in breast tumor samples and cell lines have suggested that Sox-2 has oncogenic potential in breast carcinogenesis (18-20). However, a systematic study of the expression of Oct3/4, Nanog and Sox-2 in human breast cancer cell lines has not been reported.

The present study sought to detect the expression of Oct3/4, Nanog and Sox-2 in human breast cancer cell lines. A heterogeneous population of established human breast cancer cell lines was examined to investigate the diverse expressions of Oct3/4, Nanog and Sox-2 among them.

Correspondence to: Dr Gui-Qin Ling, Department of Oncology, The Second Affiliated Hospital of Xuzhou Medical College, 32 Meijian Road, Xuzhou, Jiangsu 221006, P.R. China
E-mail: lingguiqin@126.com

Key words: breast cancer, embryonic stem cell marker, Oct3/4, Nanog, Sox-2




Figure 1. Expression levels of Oct 3/4, Nanog and Sox-2 genes in human breast cancer cell lines were detected by RT-PCR. (A) Oct3/4, Nanog and Sox-2 were expressed in breast cancer cell lines MCF7, T-47D and MDA-MB-231. The quantity of gene expression was normalized to β -actin to determine the quantitative differences among these 3 cell lines. (B) MDA-MB-231 and MCF7 cells expressed significantly higher levels of Oct3/4 than T-47D cells ($P<0.05$). (C) MCF7 and T-47D cells expressed significantly higher levels of Nanog compared with MDA-MB-231 cells ($P<0.05$). (D) MCF7 and T-47D cells expressed significantly higher levels of Sox-2 compared with MDA-MB-231 cells and the highest expression of Sox-2 was detected in MCF7 cells ($P<0.05$). RT-PCR, reverse transcription polymerase chain reaction.

Materials and methods

Cell lines and culture conditions. The human breast cancer cell lines MCF7, T-47D and MDA-MB-231 were purchased from the American Type Culture Collection (Shanghai Institute of Cellular Biology, Chinese Academy of Sciences, Shanghai, China). All cells were routinely cultured in Dulbecco's Modified Eagle's Medium (DMEM)/F12 medium (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco) in a humidified atmosphere of 5% CO₂ in air at 37°C and used when in the log phase of growth.

Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR). To assess the mRNA expression levels of Oct3/4, Nanog and Sox-2, total RNA was extracted using an RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA). Reverse transcription was performed using the SuperScript First-Strand Synthesis kit (Invitrogen, Carlsbad, CA, USA). For semiquantitative PCR, 1 μ l target cDNA conversion mixture was amplified using Hotstar Taq DNA polymerase (Qiagen, Hilden, Germany) for 35 cycles at 94°C for 30 sec, at 55°C for 30 sec and at 72°C for 1 min. The PCR primers included Oct3/4A (forward, 5'-TGGAGAAGGAGAAGCTGGAGCAAAA-3'; reverse, 5'-GGCAGAGGTCGTTTGGCTGAATAGACC-3', Genbank accession number: NM_002701), Nanog (forward, 5'-TCCTCCTCTTCTCTATACTAAC-3'; reverse, 5'-CCCACAATCACAGGCATAG-3', Genbank accession number: NM_024865) and Sox-2 (forward, 5'-GGGAAATGGAGGGTGCAAAAGAGG-3'; reverse, 5'-TTGCGTGAGTGTGGATGG GATTGGTG-3', Genbank accession number: NM_003106) and β -actin (forward, 5'-GCGGGAAATCGTGCGTGACATT-3'; reverse, 5'-GGCAGATGGTCGTTTGGCTGAATA-3', Genbank accession number: NM_001101). PCR products were electrophoresed on a 1.2% agarose gel and stained with ethidium bromide.

Immunofluorescent staining. To identify the expression of Oct3/4, Nanog and Sox-2 in breast cancer cell lines, cells were fixed in BD Cytofix/Cytoperm solution (BD Biosciences, San Jose, CA, USA) for 20 min at 4°C. Following blocking for 20 min with donkey serum (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) in BD Perm/Wash Buffer (BD Biosciences), cells were incubated with goat anti-Oct3/4 antibody (sc-8628; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and mouse anti-Sox-2 antibody (MAB-4343; 1:100; Millipore, Billerica, MA, USA) overnight at 4°C, followed by Rhodamine red conjugated donkey anti-goat antibody (1:200; Jackson ImmunoResearch Laboratories, Inc.). For Nanog staining following fixation as described above, cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-human Nanog antibody (eBioscience, Inc., San Diego, CA, USA). Negative control reactions were included in each experiment and carried out by replacing primary antibodies with PBS. Fluorescent cells were visualized and digital images were captured using an Olympus microscope.

Statistical analysis. Data are expressed as the mean \pm standard deviation (SD). Statistically significant differences were determined using SPSS version 16 software. $P<0.05$ was considered to indicate a statistically significant result.

Results

Detection of Oct 3/4, Nanog and Sox-2 in human breast cancer cell lines by RT-PCR. Oct3/4, Nanog and Sox-2 are essential transcription factors that regulate and maintain the self-renewal and pluripotency of ESCs (4). To determine whether the genes for these proteins are expressed in three breast cancer cell lines, semiquantitative RT-PCR analyses were first performed. In addition, since the existence of




Figure 2. Representative immunofluorescent staining of Oct3/4 protein expression in human breast cancer cell lines (A) MCF7, (B) T-47D, (C) MDA-MB-231. Oct3/4 expression was clearly localized in the nuclei of cells.




Figure 3. Representative immunofluorescent staining of Nanog protein expression in human breast cancer cell lines (A) MCF7, (B) T-47D, (C) MDA-MB-231. Nanog expression was clearly localized in the nuclei of cells and the Nanog-positive cells were scattered in breast cancer cells.




Figure 4. Representative immunofluorescent staining of Sox-2 protein expression in human breast cancer cell lines (A) MCF7, (B) T-47D, (C) MDA-MB-231. Sox-2 expression was clearly localized in the nuclei of cells.

2 mRNA and protein isoforms of Oct3/4 (Oct3/4A and Oct3/4B) has been validated (21), we sought to determine the gene expression of Oct3/4A specifically for the stem cell-like properties. As shown in Fig. 1A, the 3 human breast cancer cell lines tested expressed evident Oct3/4A, Nanog and Sox-2 mRNA at various expression levels. The quantity of gene expression was normalized to β -actin to determine quantitative differences among these 3 cell lines. As shown in Fig. 1B, MDA-MB-231 and MCF7 cells expressed significantly higher levels of Oct3/4A than T-47D cells ($P < 0.05$), whereas MCF7 and T-47D cells expressed significantly higher levels of Nanog compared with MDA-MB-231 cells ($P < 0.05$; Fig. 1C). MCF7 and T-47D cells expressed significantly higher levels of Sox-2 compared with MDA-MB-231 cells and the highest expression of Sox-2 was detected in

MCF7 cells ($P < 0.05$; Fig. 1D). The expression of various pluripotency marker genes was noted within the three breast cancer cell lines, suggesting that these pluripotency marker genes are reactivated during the process of breast cancer development.

Localization of Oct3/4, Nanog and Sox-2 in human breast cancer cell lines using immunofluorescence staining. To determine whether these genes were expressed at the protein level, the cells were examined using immunofluorescent staining. As shown in Fig. 2, a punctate nuclear staining of Oct3/4A was observed homogenously in all three cell lines, which is consistent with a previous study which demonstrated the same characteristic in type I breast stem cells (22). As shown in Fig. 3, bright punctate nuclear staining of Nanog was

also displayed in a small population of all 3 breast cancer cell lines tested. The Nanog-positive cells were scattered in breast cancer cells. Fig. 4 confirms nuclear staining of Sox-2 in all three cell lines.

Discussion

In cancer biology, the correlation between embryogenesis and oncogenesis has long been a prevailing theme. Cancer cells and ESCs share numerous key biological properties. A trait possessed by both cell types is extensive proliferative potential for embryogenesis and tumor development. Pluripotency is also fundamental to ESCs and gives rise to the myriad of differentiated daughter cells present in the mature embryo (23). It is important to study the pluripotency-related genes associated with embryogenesis and tumorigenesis. Transcription factors are critical molecular switches regulating ESC fate, which may also operate in renewing cancer cells. Three pluripotency-related transcription factors, Oct 3/4, Nanog and Sox-2, form a core regulatory network that coordinates to determine the self-renewal and differentiation of ESCs. These ESC self-renewal molecules may also contribute to tumorigenesis (24). The dysregulated expression of Oct 3/4, Nanog and Sox-2 has been shown in numerous types of tumors and it is possible that this may contribute to the neoplastic process and play a role in cancer development.

The purpose of the current study was to corroborate the presence of pluripotency-associated markers in human breast cancer cell lines and further investigate whether the diverse expressions of these markers relate to the inherent tumorigenicity among various breast cancer cell lines. Oct3/4 is an embryonic transcription factor highly expressed in ESCs, carcinoma cells and oocytes. Oct3/4 belongs to the POU transcription factor family and plays a critical role in maintaining the pluripotent and self-renewing state of stem cells (25). In humans, two isoforms are encoded, Oct3/4A and Oct3/4B, which share a common C-transactivation domain but have different N-transactivation domains. The existence of 2 isoforms is likely to be functionally significant but only Oct3/4A is responsible for the stem cell-like properties of cancer cells (21,26). It has been previously proposed that Oct3/4 acts as a multifunctional factor in cancer biology based on reports that Oct3/4 increases the malignant potential of ESCs in a dose-dependent manner (12,27). The expression of Oct3/4 has also been shown in some tumors and it is considered to play a critical role in tumorigenesis (6,28-32). However, Oct3/4 expression studies on tumors are generally carried out without considering the two isoforms. The current study sought to examine Oct3/4 A at the mRNA and protein levels in three human breast cancer cell lines. The results revealed that Oct3/4A was expressed in all three human breast cancer cell lines, although various expression patterns were noted. Oct3/4A was detected in the nuclei of breast cancer cells, suggesting a subset of cells with stem cell attributes were present in the breast cancer cell lines. In stem cells, Oct3/4A functions as a master switch during differentiation by regulating the pluripotent potential (33,34). Thus, the overexpression of Oct3/4A in human breast cancer cells implies a link between Oct3/4A and tumorigenesis via the activation of its downstream target genes (35). Furthermore, Oct3/4A

mRNA expression was significantly upregulated in the MCF7 and MDA-MB-231 cells compared with the T-47D cells. This suggests that there is higher OCT3/4A expression in the adenocarcinoma cells since MCF7 and MDA-MB-231 cells are derived from an adenocarcinoma. Lower Oct3/4A expression may be seen in the ductal carcinoma cells since T-47D cells are derived from a ductal carcinoma. However, further research using additional cell lines and primary tumors is required to confirm this result.

Nanog is a recently identified transcription factor and is typically expressed in ESCs. The constitutive expression of Nanog maintains the stem cell phenotype allowing for self-renewal and propagation of the cell line, even in the presence of agents that promote differentiation. The overexpression of Nanog in human ECSs promotes pluripotency and is associated with increased self-renewal capacity, whereas the knockdown of Nanog induces differentiation into mature cell types (36,37). Previous studies of Nanog in tumors have suggested its tumorigenic potential and regulation of tumor development (14,38,39). The current study demonstrated that Nanog was detected at the mRNA and protein levels in the three human breast cancer cell lines tested. The scattered Nanog-positive cells were observed in breast cancer cells by immunostaining, suggesting that Nanog is expressed only in a small subset of cancer cells. A small population of cells capable of proliferating extensively and initiating tumors are termed cancer stem cells (40). Higher expression of Nanog has also been shown in the cancer stem cells in human osteosarcoma (41). Jeter *et al* revealed that the downregulation of Nanog inhibited MCF7 breast cancer cell clonal expansion and tumor development (14). Therefore, the expression of Nanog in breast cancer cells may correlate with the tumorigenesis of breast cancer.

Sox-2, a transcription factor located on 3q26.3-q27, is one of the transcription factors expressed by stem cells. There is growing evidence to suggest that this gene is essential for the maintenance of stem cell proliferation and differentiation capabilities (42).

A number of links have been identified between Sox-2 transcription factors and human cancers (43). Sox-2 expression has been observed in embryonal carcinoma, teratoma, lung, pancreatic and gastric adenocarcinoma (44). The present study demonstrated that Sox-2 was expressed in all 3 of the human breast cancer cell lines tested. MCF7 and T-47D cells expressed significantly higher levels of Sox-2 compared with MDA-MB-231 cells. These results are consistent with a previous study by Chen *et al* (20) that identified higher Sox-2 protein expression in MCF7 and T-47D cells than in MDA-MB-231 cells. Chen *et al* further demonstrated that the downregulation of Sox-2 using si-RNA in MCF7 cells has been shown to inhibit cell proliferation and tumor growth (20). In breast cancer, Sox-2 has also been shown to be a possible driver of the basal-like phenotype and play an early role in breast carcinogenesis (18,19).

In conclusion, the present study confirms the expression of the pluripotency-associated markers Oct3/4, Nanog and Sox-2 in 3 separate breast cancer cell lines, as demonstrated by RT-PCR and immunocytochemistry. Further experiments are required to explore the complex role of Oct3/4, Nanog and Sox2 in human breast cancer.

References

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127: 2893-2917, 2010.
2. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. *Adv Exp Med Biol* 608: 1-22, 2007.
3. Ben-Porath I, Thomson MW, Carey VJ, *et al*: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nat Genet* 40: 499-507, 2008.
4. Pesce M and Schöler HR: Oct-4: gatekeeper in the beginnings of mammalian development. *Stem Cells* 19: 271-278, 2001.
5. Rodda DJ, Chew JL, Lim LH, *et al*: Transcriptional regulation of nanog by OCT4 and SOX2. *J Biol Chem* 280: 24731-24737, 2005.
6. Ezech UI, Turek PJ, Reijo RA and Clark AT: Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. *Cancer* 104: 2255-2265, 2005.
7. Hart AH, Hartley L, Parker K, *et al*: The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. *Cancer* 104: 2092-2098, 2005.
8. Hoei-Hansen CE, Almstrup K, Nielsen JE, *et al*: Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. *Histopathology* 47: 48-56, 2005.
9. Santagata S, Hornick JL and Ligon KL: Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. *Am J Surg Pathol* 30: 1613-1618, 2006.
10. Jones TD, Ulbright TM, Eble JN, Baldrige LA and Cheng L: OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. *Am J Surg Pathol* 28: 935-940, 2004.
11. Cheng L: Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. *Cancer* 101: 2006-2010, 2004.
12. Hochedlinger K, Yamada Y, Beard C and Jaenisch R: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* 121: 465-477, 2005.
13. Zhang J, Wang X, Chen B, *et al*: Expression of Nanog gene promotes NIH3T3 cell proliferation. *Biochem Biophys Res Commun* 338: 1098-1102, 2005.
14. Jeter CR, Badeaux M, Choy G, *et al*: Functional evidence that the self-renewal gene NANOG regulates human tumor development. *Stem Cells* 27: 993-1005, 2009.
15. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K and Tsutani Y: Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. *Pancreas* 32: 164-170, 2006.
16. Li XL, Eishi Y, Bai YQ, *et al*: Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. *Int J Oncol* 24: 257-263, 2004.
17. Bass AJ, Watanabe H, Mermel CH, *et al*: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. *Nat Genet* 41: 1238-1242, 2009.
18. Lengerke C, Fehm T, Kurth R, *et al*: Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. *BMC Cancer* 11: 42, 2011.
19. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, *et al*: Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. *Mod Pathol* 20: 474-481, 2007.
20. Chen Y, Shi L, Zhang L, *et al*: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. *J Biol Chem* 283: 17969-17978, 2008.
21. Lee J, Kim HK, Rho JY, Han YM and Kim J: The human OCT-4 isoforms differ in their ability to confer self-renewal. *J Biol Chem* 281: 33554-33565, 2006.
22. Tai MH, Chang CC, Kiupel M, Webster JD, Olson LK and Trosko JE: Oct4 expression in adult human stem cells: evidence in support of the stem cell theory of carcinogenesis. *Carcinogenesis* 26: 495-502, 2005.
23. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 8: 755-768, 2008.
24. Chang CC, Shieh GS, Wu P, Lin CC, Shiao AL and Wu CL: Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. *Cancer Res* 68: 6281-6291, 2008.
25. Matin MM, Walsh JR, Gokhale PJ, *et al*: Specific knockdown of Oct4 and beta2-microglobulin expression by RNA interference in human embryonic stem cells and embryonic carcinoma cells. *Stem Cells* 22: 659-668, 2004.
26. Cauffman G, Liebaers I, Van Steirteghem A and Van de Velde H: POU5F1 isoforms show different expression patterns in human embryonic stem cells and preimplantation embryos. *Stem Cells* 24: 2685-2691, 2006.
27. Gidekel S, Pizov G, Bergman Y and Pikarsky E: Oct-3/4 is a dose-dependent oncogenic fate determinant. *Cancer Cell* 4: 361-370, 2003.
28. Looijenga LH, Stoop H, de Leeuw HP, *et al*: POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. *Cancer Res* 63: 2244-2250, 2003.
29. Atlasi Y, Mowla SJ, Ziaee SA and Bahrami AR: OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. *Int J Cancer* 120: 1598-1602, 2007.
30. Seigel GM, Hackam AS, Ganguly A, Mandell LM and Gonzalez-Fernandez F: Human embryonic and neuronal stem cell markers in retinoblastoma. *Mol Vis* 13: 823-832, 2007.
31. Chiou SH, Yu CC, Huang CY, *et al*: Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. *Clin Cancer Res* 14: 4085-4095, 2008.
32. Chen YC, Hsu HS, Chen YW, *et al*: Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. *PLoS One* 3: e2637, 2008.
33. Okita K, Ichisaka T and Yamanaka S: Generation of germline-competent induced pluripotent stem cells. *Nature* 448: 313-317, 2007.
34. Park IH, Zhao R, West JA, *et al*: Reprogramming of human somatic cells to pluripotency with defined factors. *Nature* 451: 141-146, 2008.
35. Pan GJ, Chang ZY, Schöler HR and Pei D: Stem cell pluripotency and transcription factor Oct4. *Cell Res* 12: 321-329, 2002.
36. Darr H, Mayshar Y and Benvenisty N: Overexpression of NANOG in human ES cells enables feeder-free growth while inducing primitive ectoderm features. *Development* 133: 1193-1201, 2006.
37. Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J and Daley GQ: High-efficiency RNA interference in human embryonic stem cells. *Stem Cells* 23: 299-305, 2005.
38. Wang L, Park P and Lin CY: Characterization of stem cell attributes in human osteosarcoma cell lines. *Cancer Biol Ther* 8: 543-552, 2009.
39. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY and Cheung AN: Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. *Am J Pathol* 173: 1165-1172, 2008.
40. Jordan CT, Guzman ML and Noble M: Cancer stem cells. *N Engl J Med* 355: 1253-1261, 2006.
41. Wang L, Park P, Zhang H, La Marca F and Lin CY: Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. *Int J Cancer* 128: 294-303, 2011.
42. Wilbertz T, Wagner P, Petersen K, *et al*: SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. *Mod Pathol* 24: 944-953, 2011.
43. Dong C, Wilhelm D and Koopman P: Sox genes and cancer. *Cytogenet Genome Res* 105: 442-447, 2004.
44. Santagata S, Ligon KL and Hornick JL: Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. *Am J Surg Pathol* 31: 836-845, 2007.